AR109739A2 - Composiciones farmacéuticas que comprenden derivados de diosmetina - Google Patents

Composiciones farmacéuticas que comprenden derivados de diosmetina

Info

Publication number
AR109739A2
AR109739A2 ARP170102686A ARP170102686A AR109739A2 AR 109739 A2 AR109739 A2 AR 109739A2 AR P170102686 A ARP170102686 A AR P170102686A AR P170102686 A ARP170102686 A AR P170102686A AR 109739 A2 AR109739 A2 AR 109739A2
Authority
AR
Argentina
Prior art keywords
isobut
diosmetine
derivatives
pharmaceutical compositions
formula
Prior art date
Application number
ARP170102686A
Other languages
English (en)
Inventor
Franois Lefoulon
Jrme Paysant
Alain Rupin
Patricia Sansilvestri-Morel
Tony Verbeuren
Marie Boussard
- Wierzbicki Michel Franoise
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of AR109739A2 publication Critical patent/AR109739A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/06—Benzopyran radicals
    • C07H17/065—Benzo[b]pyrans
    • C07H17/07—Benzo[b]pyran-4-ones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica que comprende como ingrediente activo un compuesto de fórmula (1), en la que R¹, R² y R³, idénticos o diferentes, representan cada uno un átomo de hidrógeno o el grupo de fórmula (2), en donde el compuesto de fórmula (1) consiste en: 6,8,2’-tris-(isobut-2-en-1-il)diosmetina, ácido (5-hidroxi-2-[3-hidroxi-4-metoxi-2-(isobut-2-en-1-il)fenil]-6,8-bis(isobut-2-en-1-il)-4-oxo-4H-cromen-7-il)-b-D-glucurónico, o ácido 3-[5,7-dihidroxi-6,8-bis(isobut-2-en-1-il)-4-oxo-4H-cromen-2-il]6-metoxi-2-(isobut-2-en-1-il)fenil-b-D-glucurónico, en combinación con uno o varios excipientes o vehículos inertes, no tóxicos, aceptables farmacéuticamente.
ARP170102686A 2008-04-01 2017-09-28 Composiciones farmacéuticas que comprenden derivados de diosmetina AR109739A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801779A FR2929276B1 (fr) 2008-04-01 2008-04-01 Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
AR109739A2 true AR109739A2 (es) 2019-01-16

Family

ID=39809617

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP090101138A AR071120A1 (es) 2008-04-01 2009-03-31 Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.
ARP170102686A AR109739A2 (es) 2008-04-01 2017-09-28 Composiciones farmacéuticas que comprenden derivados de diosmetina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP090101138A AR071120A1 (es) 2008-04-01 2009-03-31 Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas.

Country Status (48)

Country Link
US (2) US8138223B2 (es)
EP (1) EP2107055B1 (es)
JP (1) JP5047211B2 (es)
KR (1) KR20120049855A (es)
CN (1) CN101550124B (es)
AP (1) AP3024A (es)
AR (2) AR071120A1 (es)
AT (1) ATE502024T1 (es)
AU (1) AU2009201068B2 (es)
BR (1) BRPI0900983B8 (es)
CA (1) CA2659947C (es)
CL (1) CL2009000757A1 (es)
CO (1) CO6150038A1 (es)
CR (1) CR10665A (es)
CU (1) CU23761B7 (es)
CY (1) CY1111367T1 (es)
DE (1) DE602009000873D1 (es)
DK (1) DK2107055T3 (es)
EA (1) EA015424B1 (es)
EC (1) ECSP099216A (es)
ES (1) ES2363196T3 (es)
FR (1) FR2929276B1 (es)
GE (1) GEP20115342B (es)
GT (1) GT200900062A (es)
HK (1) HK1136291A1 (es)
HN (1) HN2009000566A (es)
HR (1) HRP20110361T1 (es)
IL (1) IL197638A (es)
JO (1) JO2673B1 (es)
MA (1) MA31413B1 (es)
ME (1) ME00680B (es)
MX (1) MX2009003383A (es)
MY (1) MY144726A (es)
NI (1) NI200900042A (es)
NZ (1) NZ575902A (es)
PE (1) PE20091692A1 (es)
PL (1) PL2107055T3 (es)
PT (1) PT2107055E (es)
RS (1) RS51661B (es)
SA (1) SA109300201B1 (es)
SG (1) SG155849A1 (es)
SI (1) SI2107055T1 (es)
SV (1) SV2009003199A (es)
TW (1) TWI385178B (es)
UA (1) UA98623C2 (es)
UY (1) UY31712A1 (es)
WO (1) WO2009133269A1 (es)
ZA (1) ZA200901947B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2165707A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2305679A1 (en) 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
FR3002543A1 (fr) 2013-02-28 2014-08-29 Servier Lab Procede de synthese enzymatique de flavonoides, et application a la synthese de derives de diosmetine
CN106031723A (zh) * 2015-09-29 2016-10-19 西南大学 香叶木素的抗炎活性及其制剂应用
CN106822087A (zh) * 2017-01-12 2017-06-13 西南大学 香叶木素在制备治疗ⅱ型糖尿病的药物中的应用
WO2018203298A1 (en) * 2017-05-04 2018-11-08 Glenmark Pharmaceuticals S.A. Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
JP7237962B2 (ja) 2017-07-19 2023-03-13 プライマス ファーマシューティカルズ，インコーポレイティド 自己免疫性微小血管系障害を治療する方法
CN109280067B (zh) * 2017-07-21 2022-07-05 南京正大天晴制药有限公司 香叶木苷衍生物、其制备方法以及医药用途
WO2019084452A1 (en) * 2017-10-27 2019-05-02 Transfusion Health, Llc COMPOSITIONS AND METHODS FOR PRODUCING EXPANDED HEMATOPOIETIC STEM CELLS USING FLUORENE DERIVATIVES
CN109394753B (zh) * 2018-12-24 2020-10-02 武汉轻工大学 香叶木素在制备预防和/或治疗高尿酸血症肾病的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2701261B1 (fr) * 1993-02-05 1995-03-31 Adir Nouveaux composés glucuronides de la diosmétine, leur procédé de préparation et les compositions pharmaceutiques les renfermant.
FR2726273B1 (fr) * 1994-10-26 1996-12-06 Adir Nouveaux derives de la diosmetine, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2748025B1 (fr) * 1996-04-25 1998-10-30 Adir Nouveaux acides et esters de la diosmetine, et les compositions pharmaceutiques les contenant
AU756965B2 (en) * 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
GB9920912D0 (en) * 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
FR2882654B1 (fr) * 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques

Also Published As

Publication number Publication date
NI200900042A (es) 2010-03-19
CY1111367T1 (el) 2015-08-05
DE602009000873D1 (de) 2011-04-28
SV2009003199A (es) 2009-10-27
SA109300201B1 (ar) 2013-04-20
NZ575902A (en) 2010-12-24
CO6150038A1 (es) 2010-04-20
UA98623C2 (ru) 2012-06-11
EA200900397A1 (ru) 2010-10-29
AR071120A1 (es) 2010-05-26
SG155849A1 (en) 2009-10-29
MA31413B1 (fr) 2010-06-01
BRPI0900983A2 (pt) 2009-11-17
FR2929276B1 (fr) 2010-04-23
EP2107055A1 (fr) 2009-10-07
MY144726A (en) 2011-10-31
US8404742B2 (en) 2013-03-26
CU23761B7 (es) 2012-01-31
ATE502024T1 (de) 2011-04-15
HK1136291A1 (en) 2010-06-25
JO2673B1 (en) 2012-06-17
PL2107055T3 (pl) 2011-06-30
MEP10909A (xx) 2011-12-20
HRP20110361T1 (hr) 2011-06-30
CN101550124A (zh) 2009-10-07
PE20091692A1 (es) 2009-11-07
IL197638A0 (en) 2009-12-24
CA2659947C (fr) 2012-05-08
US20090247621A1 (en) 2009-10-01
AU2009201068B2 (en) 2012-11-22
PT2107055E (pt) 2011-05-09
TWI385178B (zh) 2013-02-11
AP3024A (en) 2014-11-30
ES2363196T3 (es) 2011-07-26
GEP20115342B (en) 2011-12-12
WO2009133269A1 (fr) 2009-11-05
JP5047211B2 (ja) 2012-10-10
EA015424B1 (ru) 2011-08-30
MX2009003383A (es) 2009-10-16
BRPI0900983B8 (pt) 2021-05-25
AU2009201068A1 (en) 2009-10-15
CA2659947A1 (fr) 2009-10-01
TW200944539A (en) 2009-11-01
SI2107055T1 (sl) 2011-05-31
US20120208777A1 (en) 2012-08-16
CN101550124B (zh) 2011-11-30
IL197638A (en) 2014-06-30
RS51661B (en) 2011-10-31
EP2107055B1 (fr) 2011-03-16
KR20120049855A (ko) 2012-05-17
AP2009004810A0 (en) 2009-04-30
CL2009000757A1 (es) 2010-03-26
CU20090048A7 (es) 2011-03-21
ECSP099216A (es) 2010-03-31
FR2929276A1 (fr) 2009-10-02
BRPI0900983B1 (pt) 2020-01-28
JP2009263354A (ja) 2009-11-12
HN2009000566A (es) 2011-07-11
DK2107055T3 (da) 2011-06-27
CR10665A (es) 2009-05-25
UY31712A1 (es) 2009-05-29
ME00680B (me) 2011-12-20
ZA200901947B (en) 2010-02-24
GT200900062A (es) 2011-10-13
US8138223B2 (en) 2012-03-20

Similar Documents

Publication Publication Date Title
AR109739A2 (es) Composiciones farmacéuticas que comprenden derivados de diosmetina
MX2015012062A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
GEP201706772B (en) Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
MX2015005949A (es) Nucleosidos que contienen aza-azucar antiviral.
PE20051094A1 (es) Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico y procesos para su preparacion
MX354102B (es) Derivados de bencimidazol-prolina.
MX2013001805A (es) Derivados de 2-(arilamino)-3h-imidazo [4,5-b] piridina-6-carboxamida y su uso como inhibidores de mpges-1.
MX2012001872A (es) Formulaciones intravenosas de antagonistas de neurocinina 1.
TN2012000417A1 (en) Compounds as bradykinin b1 antagonists
UY28906A1 (es) Derivados de pirimidina que son antagonistas del receptor vitronectina
WO2011044501A3 (en) Antibacterial aminoglycoside analogs
SG195106A1 (en) Trpv4 antagonists
WO2010132757A3 (en) Antibacterial aminoglycoside analogs
CO6400183A2 (es) Formas de dosificación oral de bendamustina
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
JP2014511366A5 (es)
BR112018010107A2 (pt) composição farmacêutica para o tratamento ou prevenção de nash
AR046756A1 (es) Derivados de hidronopol como agonistas de receptores orl-1 humanos.
MX2012009224A (es) Compuestos en calidad de antagonistas de bradiquinina-b1.
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
WO2014062838A3 (en) Pkm2 modulators and methods for their use
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CR20120146A (es) Derivados de espirolactama y usos de los mismos
BRPI0808377B8 (pt) composto, composição e uso de um composto

Legal Events

Date Code Title Description
FC Refusal